| 1 |
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640.
|
| 2 |
Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer[J]. Cancer Epidemiol Biomarkers Prev，2019, 28(10): 1563-1579.
|
| 3 |
刘 娜，闫 可. 非小细胞肺癌患者凝血功能变化与肿瘤恶性程度相关性分析[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(5): 563-567.
|
| 4 |
张红军，苏 尉，顾 兴，等. 癌胚抗原在不同驱动基因肺癌患者中的差异性[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 141-145.
|
| 5 |
Wadowska K, Bil-Lula I, Trembecki L, et al. Genetic markers in lung cancer diagnosis: A review[J]. Int J Mol Sci, 2020, 21(13): 4569.
|
| 6 |
Maly V, Maly O, Kolostova K, et al. Circulating tumor cells in diagnosis and treatment of lung cancer[J]. In Vivo, 2019, 33(4): 1027-1037.
|
| 7 |
Sears CR, Mazzone PJ. Biomarkers in lung cancer[J]. Clin Chest Med, 2020, 41(1): 115-127.
|
| 8 |
Goebel C, Louden CL, Mckenna RJ, et al. Diagnosis of non-small cell lung cancer for early stage asymptomatic patients[J]. Cancer Genomics Proteomics, 2019, 16(4): 229-244.
|
| 9 |
胡大山，胡建强，刘 欢，等. 肝硬化腹水患者的临床特征新趋势[J]. 肝脏，2019, 24(2): 181-184.
|
| 10 |
李广平，张红心，张 蕾，等. 透明质酸、Ⅳ型胶原、APRI及纤维蛋白原-4对乙型肝炎后肝纤维化的诊断价值[J]. 临床和实验医学杂志，2021, 20(13): 1385-1388.
|
| 11 |
岳瀚勋，余 娴，赵 轩，等. 自组装形成的透明质酸-铜-槲皮素配位聚合物纳米粒子对乳腺癌的协同治疗作用[J]. 川北医学院学报，2021, 36(9): 1187-1191.
|
| 12 |
王燕忠，吴伟平，金 晶，等. 术前血清透明质酸水平与乳腺癌患者预后的相关性分析[J]. 中华预防医学杂志，2020, 54(9): 993-997.
|
| 13 |
中华医学会，中华医学会肿瘤学分会，中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志，2020, 42(4): 257-287.
|
| 14 |
Thakur SK, Singh DP, Choudhary J. Lung cancer identification: a review on detection and classification[J]. Cancer Metastasis Rev, 2020, 39(3): 989-998.
|
| 15 |
Toumazis I, Bastani M, Han SS, et al. Risk-Based lung cancer screening: A systematic review[J]. Lung Cancer, 2020, 147(1): 154-186.
|
| 16 |
Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices[J]. Am Soc Clin Oncol Educ Book, 2019, 39(3): 531-542.
|
| 17 |
Yatabe Y, Dacic S, Borczuk AC, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer[J]. J Thorac Oncol, 2019, 14(3): 377-407.
|
| 18 |
Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era[J]. Mod Pathol, 2019, 32(1): 16-26.
|
| 19 |
石烟祝，陈静漪，蒋琦炜，等. 透明质酸介导运动受体真核表达载体的构建及其对乳腺癌增殖和迁移的影响[J]. 军事医学，2021, 45(3): 241-245.
|
| 20 |
郝利铭，姜 晶，赵广鑫，等. 不同分子量透明质酸对肺癌小鼠体内肿瘤生长转移的影响[J]. 吉林医药学院学报，2020, 41(3): 161-165.
|
| 21 |
董 芸，袁峥玺，姚 原. 肿瘤标志物SCC-Ag、Cyf21-1、CEA、ProGRP、及NSE联合检测在肺癌诊断中的应用[J]. 中国实验诊断学，2019, 23(3): 384-386.
|
| 22 |
陈全敏，周 峰，刘 阳，等. MSCT联合血清HE4、CEA及Cyfra21-1因子检测对肺癌中的诊断价值[J]. 中国CT和MRI杂志，2021, 19(10): 43-45.
|
| 23 |
张晓玲. 小细胞肺癌患者血清NSE、SCC的表达水平变化及其临床意义[J]. 实用癌症杂志，2018, 33(5): 739-741.
|
| 24 |
许 涛，杨 磊，刘兴田. 血清CA125、SCCA在肺结核与肺癌患者中的表达对比分析[J]. 临床肺科杂志，2021, 26(5): 738-741.
|
| 25 |
李 涛，母前途，唐 蕾. 血清肿瘤标志物CEA、ProGRP、SCC水平联合测定MSCT检查对肺癌的诊断效能分析[J]. 中国CT和MRI杂志，2021, 19(11): 68-69.
|
| 26 |
常雨薇，曹鸿鑫，李王斌，等. 肺癌患者淋巴细胞腺苷脱氨酶活性变化及其对炎性细胞因子的影响[J]. 山西医药杂志，2021, 50(5): 816-818.
|
| 27 |
Lozano MD, Echeveste JI, Abengozar M, et al. Cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less[J]. Arch Pathol Lab Med, 2018, 142(3): 291-298.
|
| 28 |
Jain D, Roy-Chowdhuri S. Molecular pathology of lung cancer cytology specimens: a concise review[J]. Arch Pathol Lab Med, 2018, 142(9): 1127-1133.
|
| 29 |
Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide[J]. Am J Clin Pathol, 2012, 138(3): 332-346.
|
| 30 |
Doxtader EE, Cheng YW, Zhang Y. Molecular testing of non-small cell lung carcinoma diagnosed by endobronchial ultrasound-guided transbronchial fine-needle aspiration: the cleveland clinic experience[J]. Arch Pathol Lab Med, 2019, 143(6): 670-676.
|